全文获取类型
收费全文 | 731621篇 |
免费 | 43179篇 |
国内免费 | 1202篇 |
专业分类
耳鼻咽喉 | 8915篇 |
儿科学 | 22229篇 |
妇产科学 | 16701篇 |
基础医学 | 118698篇 |
口腔科学 | 16734篇 |
临床医学 | 67924篇 |
内科学 | 138161篇 |
皮肤病学 | 14567篇 |
神经病学 | 53749篇 |
特种医学 | 26391篇 |
外国民族医学 | 66篇 |
外科学 | 109612篇 |
综合类 | 10922篇 |
现状与发展 | 4篇 |
一般理论 | 394篇 |
预防医学 | 57160篇 |
眼科学 | 16084篇 |
药学 | 55333篇 |
2篇 | |
中国医学 | 1498篇 |
肿瘤学 | 40858篇 |
出版年
2021年 | 7155篇 |
2019年 | 7112篇 |
2018年 | 9499篇 |
2017年 | 7195篇 |
2016年 | 8130篇 |
2015年 | 9252篇 |
2014年 | 12954篇 |
2013年 | 18989篇 |
2012年 | 28091篇 |
2011年 | 31120篇 |
2010年 | 17758篇 |
2009年 | 15850篇 |
2008年 | 28785篇 |
2007年 | 31282篇 |
2006年 | 30285篇 |
2005年 | 30095篇 |
2004年 | 29233篇 |
2003年 | 27783篇 |
2002年 | 26835篇 |
2001年 | 24250篇 |
2000年 | 24396篇 |
1999年 | 20916篇 |
1998年 | 7962篇 |
1997年 | 6734篇 |
1996年 | 6528篇 |
1995年 | 6019篇 |
1994年 | 5384篇 |
1992年 | 15587篇 |
1991年 | 16930篇 |
1990年 | 16968篇 |
1989年 | 16547篇 |
1988年 | 15281篇 |
1987年 | 15182篇 |
1986年 | 14129篇 |
1985年 | 13736篇 |
1984年 | 10829篇 |
1983年 | 9419篇 |
1982年 | 5944篇 |
1981年 | 5413篇 |
1979年 | 9723篇 |
1978年 | 7315篇 |
1977年 | 6056篇 |
1976年 | 6317篇 |
1975年 | 7273篇 |
1974年 | 8075篇 |
1973年 | 7735篇 |
1972年 | 7017篇 |
1971年 | 6649篇 |
1970年 | 6213篇 |
1969年 | 5703篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
92.
93.
Altan Ahmed John A. Stauffer Jordan D. LeGout Justin Burns Kristopher Croome Ricardo Paz-Fumagalli Gregory Frey Beau Toskich 《Journal of gastrointestinal oncology.》2021,12(2):751
BackgroundNeoadjuvant yttrium-90 transarterial radioembolization (TARE) is increasingly being used as a strategy to facilitate resection of otherwise unresectable tumors due to its ability to generate both tumor response and remnant liver hypertrophy. Perioperative outcomes after the use of neoadjuvant lobar TARE remain underinvestigated.MethodsA single center retrospective review of patients who underwent lobar TARE prior to major hepatectomy for primary or metastatic liver cancer between 2007 and 2018 was conducted. Baseline demographics, radioembolization parameters, pre- and post-radioembolization volumetrics, intra-operative surgical data, adverse events, and post-operative outcomes were analyzed.ResultsTwenty-six patients underwent major hepatectomy after neoadjuvant lobar TARE. The mean age was 58.3 years (17–88 years). 62% of patients (n=16) had primary liver malignancies while the remainder had metastatic disease. Liver resection included right hepatectomy or trisegmentectomy, left or extended left hepatectomy, and sectorectomy/segmentectomy in 77% (n=20), 8% (n=2), and 15% (n=4) of patients, respectively. The mean length of stay was 8.3 days (range, 3–33 days) and there were no grade IV morbidities or 90-day mortalities. The incidence of post hepatectomy liver failure (PHLF) was 3.8% (n=1). The median time to progression after resection was 4.5 months (range, 3.3–10 months). Twenty-three percent (n=6) of patients had no recurrence. The median survival was 28.9 months (range, 16.9–46.8 months) from major hepatectomy and 37.6 months (range, 25.2–53.1 months) from TARE.ConclusionsMajor hepatectomy after neoadjuvant lobar radioembolization is safe with a low incidence of PHLF. 相似文献
94.
95.
96.
97.
98.
99.
Roberto V.P. Ribeiro Mitesh V. Badiwala Danny Ramzy Laura C. Tumiati Vivek Rao 《The Journal of thoracic and cardiovascular surgery》2019,157(2):615-625.e1
Objective
Hypertonic saline (HTS) has potent immune and vascular effects. We assessed recipient pretreatment with HTS on allograft function in a porcine model of heart transplantation and hypothesized that HTS infusion would limit endothelial and left ventricular (LV) dysfunction following transplantation.Methods
Heart transplants were performed after 6 hours of cold ischemic storage. Recipient pigs were randomized to treatment with or without HTS (7.5% NaCl) before cardiopulmonary bypass (CPB). Using a myograft apparatus, coronary artery endothelial-dependent (Edep) and -independent (Eind) relaxation was assessed. LV performance was determined using pressure-volume loop analysis. Pulmonary interleukin (IL)-2, IL-6, and tumor necrosis factor (TNF)-α expression was measured.Results
Weaning from CPB and LV performance after transplantation were improved in HTS-treated animals. Successful weaning from CPB was greater in the HTS-treated hearts (8 of 8 vs 2 of 8; P < .05). Mean LV functional recovery was improved in the HTS-treated animals, as assessed by preload recruitable stroke work (65 ± 10% vs 27 ± 10%; P < .001) and end-systolic elastance (55 ± 7% vs 37 ± 4%; P < .001). Treatment with HTS resulted in improved Edep (mean maximum elastance [Emax], 56 ± 5% vs 37 ± 7%; P < .001) and Eind (mean Emax%, 77 ± 6% vs 52 ± 4%; P < .001) vasorelaxation compared with control. Pulmonary expression of IL-2, IL-6, and TNF-α increased following transplantation, whereas HTS therapy attenuated IL production (P < .001). Transplantation increased plasma TNF-α levels and LV TNF-α expression, whereas HTS prevented this up-regulation (P < .001).Conclusions
Recipient HTS pretreatment preserves allograft vasomotor and LV function, and HTS therapy limits CPB-induced injury. HTS may be a novel recipient intervention to prevent graft dysfunction. 相似文献100.
Lesley A. Inker Morgan E. Grams Andrew S. Levey Josef Coresh Massimo Cirillo John F. Collins Ron T. Gansevoort Orlando M. Gutierrez Takayuki Hamano Gunnar H. Heine Shizukiyo Ishikawa Sun Ha Jee Florian Kronenberg Martin J. Landray Katsuyuki Miura Girish N. Nadkarni Carmen A. Peralta Dietrich Rothenbacher Mark Woodward 《American journal of kidney diseases》2019,73(2):206-217